Immunotherapy in Melanoma | Specialty

Dr. Keith Flaherty Discusses Long-Term Data from the COLUMBUS Trial

November 10th 2016

Keith T. Flaherty, MD, director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and professor of Medicine, Harvard Medical School, discusses the results from the COLUMBUS trial, testing encorafenib plus binimetinib compared to vemurafenib or encorafenib as single agents.

Bin Zheng on the Potential of Diabetes Drugs in Melanoma

November 10th 2016

Bin Zheng, PhD, assistant professor of Dermatology at Harvard Medical School and assistant biologist at Massachusetts General Hospital, discusses the potential for phenformin, a drug created for Type 2 diabetes, to be used for patients with melanoma.

Encorafenib/Binimetinib Highly Effective in BRAF-mutant Melanoma

November 9th 2016

The combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib reduced the risk of progression or death by 46% compared with vemurafenib (Zelboraf) for patients with BRAF-mutant unresectable melanoma.

Nilotinib/Trametinib Show Early Promise in BRAF/NRAS Wild-Type Melanoma

November 9th 2016

The combination of nilotinib and trametinib proved to be synergistic in BRAF/NRAS wild-type melanoma.

Dabrafenib/Trametinib OS Duration Associated With Number of Metastatic Melanoma Sites

November 9th 2016

The combination of dabrafenib and trametinib continued to demonstrate durable efficacy for patients with BRAF V600E/K-mutant melanoma across patient subgroups in a 3-year analysis of the phase III COMBI-d study, with baseline site of metastasis identified as a predictor of overall survival ≥36 months,

Graham Mann on Genetic Mutations in Different Types of Melanoma

November 9th 2016

Graham Mann, MBBS, PhD, FRACP, professor of Medicine, Westmead Clinical School and co-director of the Centre for Cancer Research, The Westmead Institute for Medical Research at the University of Sydney in Australia, discusses his findings from the Australian Melanoma Genome Project, which were presented at the 2016 Society for Melanoma Research (SMR) Congress.

Stefani Spranger Explores the Absence of T Cells in Melanoma Subtypes

November 9th 2016

Stefani Spranger, PhD, postdoctoral fellow at the University of Chicago, discusses recent findings about why a certain subgroup of patients with melanoma do not have T cells within their tumor microenvironment.

Expert Highlights Resistance to Targeted Therapies, Role of Epigenetic Changes in Melanoma

November 8th 2016

Helmut Schiader, MD, discusses why drug resistance may be due to epigenetic changes and not mutation-induced changes, as well as the role of immunotherapy/targeted therapy combinations in combating resistance.

Final Thoughts on STS

November 8th 2016

Toxicity of Olaratumab and Doxorubicin

November 8th 2016

Sequencing with Olaratumab in STS

November 8th 2016

Appropriate Patients for Olaratumab + Doxorubicin

November 8th 2016

OS vs PFS with Olaratumab

November 8th 2016

Practical Implications of Using Olaratumab in Patients with STS

November 8th 2016

Registration Trials for Olaratumab and Doxorubicin for STS

November 8th 2016

FDA Approval of Olaratumab + Doxorubicin for STS

November 8th 2016

Multidisciplinary Care of STS

November 8th 2016

Disease State: Advanced Soft Tissue Sarcoma

November 8th 2016

Immunotherapy, MEK Inhibitor Combo Effective for BRAF Wild-Type Melanoma

November 8th 2016

The combination of atezolizumab and cobimetinib may lead to a higher overall response and a longer progression-free survival than either agent alone in patients with metastatic melanoma.

Dr. Christian Blank on Combining Immunotherapy Agents in High-Risk Melanoma

November 8th 2016

Christian Blank, MD, PhD, Netherlands Cancer Institute, discusses some of the early findings from the OpACIN trial testing a combination of ipilimumab and nivolumab in the neoadjuvant and adjuvant setting for patients with stage III melanoma.